Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.49.5
PrivacidadTérminosCookiesAviso Legal
● Connected
ZEOX US Equity
Zeo ScientifiX, Inc.
1.15USD▼ 2.95%
Healthcare
Biotechnology
96)Comparar97)Tesis →
Market Cap
$9M
Shares Outstanding
8M
Revenue (TTM)
$7M
Net Income (TTM)
−$4M
— Annual —FY2025
Revenue
$5M
Gross Margin
82.1%
Operating Margin
-103.6%
Net Margin
-106.2%
FCF Margin
-14.3%
ROCE
400.1%
Current Ratio
0.33
FCF / Share
-0.09
Book Value / Share
-0.18
ZEOX US Equity
1.15USD▼ 2.95%
Tesis →

Zeo ScientifiX, Inc. (ZEOX): análisis fundamental y valoración

Zeo ScientifiX, Inc. cotiza a 1.15 USD y tiene una capitalización bursátil de $9M. En los últimos 12 meses ha facturado $7M con un margen de flujo de caja libre del -14.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaOTCPaísUnited StatesEmpleados20Beta1.74Web↗ www.zeoscientifix.com

Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II cli…

Múltiplos de Valoración
P/E (Annual)
—
P/E (TTM)
—
P/FCF (Annual)
—
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
—
P/Sales
1.7×
P/Book
—
Rentabilidad (Último Anual)
Gross Margin
82.1%
Operating Margin
-103.6%
Net Margin
-106.2%
FCF Margin
-14.3%
ROE
—
ROCE
400.1%
ROA
-361.6%
Effective Tax Rate
—
Métricas TTM
Revenue TTM
$7M
Gross Profit TTM
$6M
Operating Income TTM
−$4M
Net Income TTM
−$4M
FCF TTM
—
EPS TTM
-0.58
Quarters Used
4
TTM Period
2025-07-31 → 2026-04-30
Solidez del Balance
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Current Ratio
0.33
Interest Coverage
-55.0×
Working Capital
−$2M
Book Value / Share
-0.18
Net Debt / Share
—
Crecimiento (YoY)
Revenue YoY
+12.5%
Net Income YoY
-17.3%
FCF YoY
—
EPS Diluted YoY
-16.2%
Retorno al Accionista
Dividend Yield
—
Payout Ratio
—
FCF / Share
-0.09
CapEx % Revenue
0.4%
Rev / Employee
259,950
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaZEOXMediana SectorΔ
Gross Margin82.1%57.0%+25.1%
Operating Margin-103.6%-38.6%-65.0%
Net Margin-106.2%-33.6%-72.6%
FCF Margin-14.3%-13.9%-0.4%
ROE—-40.4%—
ROA-361.6%-32.0%-329.6%
Current Ratio0.332.84-2.51
Debt / Equity—0.28—
Scoring Fundamental
Capital Allocation
3/ 8Débil
✗FCF+Free cash flow positivo
✗FCFmMargen FCF > 10%
✓DilucSin dilución significativa (< 2%/año en 3 años)
✗Rev↑Revenue CAGR 3 años > 5%
✓ROCERetorno sobre capital empleado > 10%
✗DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✓Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✗Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)